Abstract.
Glutamic acid decarboxylase (GAD) is the enzyme that catalyses the production of GABA, a major neurotransmitter of the central nervous system. Antibodies to GAD (GAD-Ab) were first recognised in a patient affected by stiff-person syndrome; subsequently they were reported in a large number of cases with type 1 diabetes. Recently GADAb have been described in a number of patients affected by chronic cerebellar ataxia, drug-resistant epilepsy and myoclonus. These cases usually harbour other autoantibodies or are affected by organ-specific autoimmune diseases. The role of GAD-Ab is still unclear; the lack of experimental models makes it difficult to investigate their potential pathogenetic role. However two mechanisms have been suggested: the reduction by GAD-Ab of GABA synthesis in nerve terminals or the interference with exocytosis of GABA.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Author information
Authors and Affiliations
Additional information
Received: 16 May 2002 / Accepted in revised form: 10 July 2002
Correspondence to B. Giometto
Rights and permissions
About this article
Cite this article
Vianello, M., Tavolato, B. & Giometto, B. Glutamic acid decarboxylase autoantibodies and neurological disorders. Neurol Sci 23, 145–151 (2002). https://doi.org/10.1007/s100720200055
Issue Date:
DOI: https://doi.org/10.1007/s100720200055